Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on March 25, 2008
JNCI Journal of the National Cancer Institute 2008 100(7):459-461; doi:10.1093/jnci/djn092
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
100/7/459    most recent
djn092v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Anthracycline Therapy May Be Avoidable in Early Breast Cancer, New Studies Suggest

Rabiya Tuma

The first 10% of the full text of this article appears below.

Several meta-analyses have shown that the overall outlook for women diagnosed with early breast cancer has improved in recent decades, with better overall survival and fewer relapses. Anthracycline-based therapy, the backbone of early breast cancer treatment, has undoubtedly been a major driving force in those improvements. Yet the drugs also cause long-term heart problems and secondary leukemia in some patients. Researchers are therefore trying to identify equally effective regimens that lack those side effects.

Nonanthracycline regimens that have less long-term toxicity may provide equal clinical benefit in terms of prolonged progression-free and overall survival, according to data presented at the San Antonio Breast Cancer Symposium in December 2007. Given those results and a recently published meta-analysis, some experts are calling for a change in the standard of care: leaving . . . [Full Text of this Article]

Anthracycline Alternative?

Anthracycline Benefit Restricted to Subset of HER2


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?